Are you aging faster and then taking steps to prevent those organs from worsening? So, for example, if a person’s biomarker shows that their liver is aging faster than their other organs, the doctor can recommend lifestyle changes such as reducing alcohol consumption and increasing exercise. Similarly, if the brain is aging faster, the doctor can recommend brain exercises and cognitive training to slow the aging process.
Moreover, this biomarker can also be used to customize medications and therapies based on a person’s unique needs. For instance, if a person’s biomarker shows that their kidneys are aging faster, the doctor can prescribe a medication explicitly targeting the kidneys to prevent further damage. Essentially, this biomarker can help shift our focus from a one-size-fits-all approach to a more personalized one where treatments are tailored to an individual’s needs.
In conclusion, longevity medicine and biomarkers for aging hold immense promise for extending our lifespan and improving our health. With the development of biomarkers like the aging biomarker discussed in this article, it is possible to identify and address aging-related health issues before they reach a critical stage. This not only increases our chances of living longer but also living a healthier life. So, let’s embrace the advancements in medical science and take steps to make the most of our time on this earth.
*****
*****
Summary of Transcript:
The video discusses the potential for people to live to the age of 200 through longevity medicine. The presenter explains that metformin can allow people to live up to 10 years longer and reduce the risk of developing certain diseases. However, conducting a clinical trial for the drug would require about 20 years and $50 billion. The solution to this problem is using aging biomarkers, which can predict how quickly or slowly different organs are aging through a single blood draw. The presenter has developed an aging biomarker that can predict aging in 11 different organs, and this can be done for under $20. The biomarkers are sensitive and can detect tiny changes, making it possible to track the effectiveness of a drug trial in a shorter period with smaller sample sizes. The biomarkers can also have potential uses in preventative medicine.
*****
Summary of Description:
Raghav Sehgal is a Ph.D. student at Yale University who is developing the next generation of Epigenetic based Aging Biomarkers, a technology that aims to slow, stop, and even reverse the biological processes that cause human aging. He discusses the heterogeneity in aging and genotypes and the link between aging and diseases such as cancer, diabetes, and Alzheimer’s. As an expert in Computational Biomedical technologies, Sehgal embeds Data Science and Artificial Intelligence in the Biomedical space to transform human health. He has received funding from the Gruber fellowship and Impetus Aging grant for his work. As a fellow at Yale’s tech transfer and investments office, Sehgal is also deeply involved in Yale’s entrepreneurship and investment ecosystem. His ultimate goal is to identify and build the next generation of technologies that will transform human health.
*****
Source Description
Raghav discusses entrepreneurship and his work developing the next generation of Epigenetic based Aging Biomarkers, a new technology that will transform human health. He examines questions such as “How do humans age?”, “How does aging lead to various diseases such as Cancer, Diabetes, Cardiovascular disease, Alzheimer’s, and other aging-related diseases?” and “Can we slow, stop and even reverse the biological processes that cause human aging?”. Raghav Sehgal is a Ph.D. student at Yale University and an expert in Computational Biomedical technologies with over a decade of experience embedding Data Science and Artificial Intelligence in the Biomedical space. Over the last few years, Raghav has been using his skills to build the next generation of Epigenetic based Aging Biomarkers that explain heterogeneity in Aging and Ageotypes, for which he has received funding from the Gruber fellowship, Impetus Aging grant, and more. Raghav has also been closely involved in building and managing a $100 million Biomedical Data Science startup called Elucidata and is a scientific advisor at LongevityTech. Raghav is also deeply involved in Yale’s entrepreneurship and investment ecosystem as a fellow at Yale’s tech transfer and investments office. His ultimate goal through his work is to identify and build the next generation of technologies that will transform human health. This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at https://www.ted.com/tedx.
